Recombinant Human IL2RA Protein, DYKDDDDK-tagged

• Cat.No.: IL2RA-151H
• Product Overview: Recombinant Human interleukin 2 receptor, alpha(IL2RA) protein, transcript variant 1 (NM_000417), with a DYKDDDDK tag, was expressed in human cells.

Specification

• Description: The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency.
• Source: Human Cells
• Species: Human
• Tag: Flag
• Form: Purified protein formulated in a sterile solution of TBS buffer, pH7.217, without any preservatives.
• Molecular Mass: 24.8 kDa
• Endotoxin: Endotoxin level is < 0.1 ng/µg of protein (<1EU /µg)
• Purity: >90% by SDS-PAGE gel and Coomassie Blue staining
• Applications: Antigens, Western, ELISA and other in vitro binding or in vivo functional assays, and protein-protein interaction studies.

Gene Information

• Gene Name: IL2RA interleukin 2 receptor, alpha [ Homo sapiens ]
• Official Symbol: IL2RA
• Synonyms: IL2RA; interleukin 2 receptor, alpha; IL2R; interleukin-2 receptor subunit alpha; CD25; p55; IL2-RA; IL-2-RA; TAC antigen; IL-2R subunit alpha; IL-2 receptor subunit alpha; TCGFR; IDDM10
• Gene ID: 3559
• mRNA Refseq: NM_000417
• Protein Refseq: NP_000408
• MIM: 147730
• UniProt ID: P01589

Reviews

09/29/2022

Security is very high and can be used with confidence.

06/05/2021

Structure is very stable and not prone to mutation.

03/14/2019

The amount of expression is very high and can be easily detected.

Q&As

Is there any adverse effect of IL2RA combined with other drugs?

The combination of IL2RA and other drugs may produce nausea, vomiting, rash and other adverse reactions, should be monitored.

How often is IL2RA used?

The frequency of use of IL2RA depends on the specific situation of the patient, and is generally used 1-3 times per week.

Whether there is an effect of IL2RA?

IL2RA, in the right dosage and frequency of use, can significantly relieve symptoms of diseases such as autoimmune diseases and organ transplant rejection.

Can IL2RA treat cancer?

Can assist in the treatment of some types of malignant tumors, but it is not a complete cure for cancer.

How effective is IL2RA treatment?

The effective rate of IL2RA therapy depends on many factors such as the type of disease, the patient's condition and the treatment regimen, and the effective rate is generally between 50% and 90%.

What are the indications for IL2RA?

Indications of IL2RA include a variety of autoimmune diseases, organ transplant rejection and malignant tumors.